Amneal Takes A Step Forward On Biosimilars
FDA Accepts Filing For Bevacizumab Rival To Avastin, Partnered With Mabxience
Executive Summary
The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.
You may also be interested in...
Baclofen Deal Offers Amneal Biosimilars Advantage
Amneal says an $83.5m deal to acquire Saol Therapeutics’ baclofen franchise will also bring the firm an “experienced institutional commercial team” that will be able to support three biosimilar launches that the company now expects to execute in 2022.
Apotex Begins Roll Out Of Avastin Biosimilar In Canada
Following recent Health Canada approval, Apotex has launched partner mAbxience’s Bambevi (bevacizumab) biosimilar across Canada, adding to its portfolio of biosimilars that includes both filgrastim and pegfilgrastim.
Amneal Plans ‘Meaningful Additions’ To Its Generics Portfolio
Amneal continues to focus on new generics launches as the company sees its quarterly and half-yearly revenues increase on the back of its new launches and generics portfolio. The US-based company said that it was looking to continue its shift towards complex generics, as it considers eventually building in-house capabilities for biosimilars.